N-(2-acetamidopyridin-4-yl)-2,6-dichlorobenzamide | 1258292-38-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(2-acetamidopyridin-4-yl)-2,6-dichlorobenzamide
• CAS: 1258292-38-4
• 化学式: C₁₄H₁₁Cl₂N₃O₂
• 分子量: 324.166
• InChiKey: DKNAYSZNMZIMIZ-UHFFFAOYSA-N

物化性质

• 沸点：
  483.8±45.0 °C(Predicted)
• 密度：
  1.483±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  71.1
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2,6-二氯苯甲酰氯 在 吡啶 、 tris-(dibenzylideneacetone)dipalladium(0) 、 sodium hydride 、 lithium hexamethyldisilazane 、 2-二环己膦基-2'-(N,N-二甲胺)-联苯 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 19.33h， 生成 N-(2-acetamidopyridin-4-yl)-2,6-dichlorobenzamide
  参考文献：
  名称：

  Lead identification of novel and selective TYK2 inhibitors

  摘要：

  A therapeutic rationale is proposed for the treatment of inflammatory diseases, such as psoriasis and inflammatory bowel diseases (IBD), by selective targeting of TYK2. Hit triage, following a high-throughput screen for TYK2 inhibitors, revealed pyridine I as a promising starting point for lead identification. Initial expansion of 3 separate regions of the molecule led to eventual identification of cyclopropyl amide 46, a potent lead analog with good kinase selectivity, physicochemical properties, and pharmacokinetic profile. Analysis of the binding modes of the series in TYK2 and JAK2 crystal structures revealed key interactions leading to good TYK2 potency and design options for future optimization of selectivity. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.03.070

文献信息

• JANUS KINASE INHIBITOR COMPOUNDS AND METHODS
  申请人：GOODACRE SIMON CHARLES

  公开号：US20100317643A1

  公开（公告）日：2010-12-16

  The invention provides compounds of Formula I, stereoisomers or pharmaceutically acceptable salts thereof, wherein A, B, D, R 1 , R 2 , R 4 and R 5 are defined herein, a pharmaceutical composition that includes a compound of Formula I and methods of use thereof

  这项发明提供了公式I的化合物，其立体异构体或药学上可接受的盐，其中A、B、D、R1、R2、R4和R5在此处被定义，包括公式I化合物的药物组合物以及其使用方法
• US8486950B2
  申请人：——

  公开号：US8486950B2

  公开（公告）日：2013-07-16
• [EN] JANUS KINASE INHIBITOR COMPOUNDS AND METHODS<br/>[FR] COMPOSÉS INHIBITEURS DES KINASES JANUS ET PROCÉDÉS
  申请人：HOFFMANN LA ROCHE

  公开号：WO2010142752A1

  公开（公告）日：2010-12-16

  The invention provides compounds of Formula (I), stereoisomers or pharmaceutically acceptable salts thereof, wherein A, B, D, R1, R2, R4 and R5 are defined herein, a pharmaceutical composition that includes a compound of Formula (I), methods of making those compounds as well as methods of use thereof
• Lead identification of novel and selective TYK2 inhibitors
  作者：Jun Liang、Vickie Tsui、Anne Van Abbema、Liang Bao、Kathy Barrett、Maureen Beresini、Leo Berezhkovskiy、Wade S. Blair、Christine Chang、James Driscoll、Charles Eigenbrot、Nico Ghilardi、Paul Gibbons、Jason Halladay、Adam Johnson、Pawan Bir Kohli、Yingjie Lai、Marya Liimatta、Priscilla Mantik、Kapil Menghrajani、Jeremy Murray、Amy Sambrone、Yisong Xiao、Steven Shia、Young Shin、Jan Smith、Sue Sohn、Mark Stanley、Mark Ultsch、Birong Zhang、Lawren C. Wu、Steven Magnuson

  DOI：10.1016/j.ejmech.2013.03.070

  日期：2013.9

  A therapeutic rationale is proposed for the treatment of inflammatory diseases, such as psoriasis and inflammatory bowel diseases (IBD), by selective targeting of TYK2. Hit triage, following a high-throughput screen for TYK2 inhibitors, revealed pyridine I as a promising starting point for lead identification. Initial expansion of 3 separate regions of the molecule led to eventual identification of cyclopropyl amide 46, a potent lead analog with good kinase selectivity, physicochemical properties, and pharmacokinetic profile. Analysis of the binding modes of the series in TYK2 and JAK2 crystal structures revealed key interactions leading to good TYK2 potency and design options for future optimization of selectivity. (C) 2013 Elsevier Masson SAS. All rights reserved.